Read/Post Comments (0) | Recommended this article (0)
Please login to Zacks.com or register to post a comment.
Zacks' 7 Best Stocks
for June, 2013
FREE Report for Zacks.com
Visitors Only
Visitors Only
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
- Latest News
- Most Popular
- FED Front & Center Again
- Roundtable Top Picks of the Week
- RTI: Sector Strength Charts - Where's the Opportunity Now?
- Surging Financial ETFs Beating the Market
- Utility Industry Stock Outlook - June 2013
- 3 Japanese Stocks to Buy Now
- Your Next Stock Should Be Making New Highs
- Anatomy of Success: Stoneridge (SRI)
- RTI: What Will the Fed Do Wednesday?
- AWS 6/19: Will Bernanke Clarify Matters Today?
- PFP 6/19: Investors Bold in Wake of the Fed
Recent Quotes
| No Recent Quote currently available |
My Portfolio
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
Zacks #1 Stocks on the Move 06/19/2013
| Company Name | Symbol | %Change |
|---|---|---|
| SONIC FOUNDR | SOFO | 4.69% |
| SUMITOMO MIT | SMFG | 3.61% |
| SUPPORTCOM I | SPRT | 3.53% |
| NIPPON TELEG | NTT | 3.03% |
| TOKIO MARINE | TKOMY | 2.99% |
Quick Links
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
InterMune Inc. (ITMN - Snapshot Report) recently completed the sale of its rights to Actimmune to Vidara Therapeutics International Limited for $55 million plus royalties. Vidara is part of an international group of companies operating in the US and Ireland.
The Agreement
As per the agreement, InterMune received $55 million in cash from Vidara. Moreover InterMune will receive royalty payments on Actimmune sales over a two-year period. InterMune expects royalty payments to be around $2–$4 million over the period.
Actimmune is approved for the treatment of chronic granulomatous disease (CGD) and severe, malignant osteoporosis. Actimmune sales for the year 2011 were $20.2 million. Management nonetheless conceded that Actimmune has so far been the company’s tactical financial asset. We believe that the sale of Actimmune will allow InterMune to focus on marketing its lead drug Esbriet (pirfenidone in the US). Esbriet is available in Germany for treating patients suffering from idiopathic pulmonary fibrosis (IPF). Esbriet is expected to be launched in other EU nations during the course of the year.
Expense Guidance for 2012
Apart from announcing the closure of the divestment, InterMune also adjusted its guidance for operating expenses in 2012. The company currently expects research and development (R&D) expenses in the range of $90–$105 million (old guidance: $95–$115 million) this year. The increase was primarily attributable to the expenses expected to be incurred in relation to the phase III study (ASCEND) to support the approval of pirfenidone for treating IPF patients in the US. The enrollment for the study is expected to be completed by the end of this year. We remind investors that the US Food and Drug Administration (FDA) issued a complete response letter (CRL) in May 2010 for Esbriet. Moreover, the delay of investments related to certain non-Esbriet R&D activities also contributed to the increased guidance.
InterMune forecasts selling general and administrative (SG&A) in 2012 in the range of $110–$130 million (old guidance: $120–$145 million). The decrease was attributable to the pricing and reimbursement discussions for Esbriet in Europe.
Our Recommendation
We currently have a Neutral recommendation on InterMune, which carries a Zacks #3 Rank (short-term ‘Hold’ rating).
Get the full Snapshot Report on ITMN - FREE